Workflow
Blueprint Medicines(BPMC)
icon
Search documents
Blueprint Medicines(BPMC) - 2021 Q3 - Quarterly Report
2021-10-27 16:00
Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of ...
Blueprint Medicines(BPMC) - 2021 Q2 - Earnings Call Transcript
2021-07-29 19:47
Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2021 Earnings Conference Call July 29, 2021 8:30 AM ET Company Participants Kristin Hodous - Senior Manager-Investor Relations Jeff Albers - Chief Executive Officer Christy Rossi - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Marc Frahm - Cowen Dane Leone - Raymond James Reni Benjamin - JMP Securities Peter Lawson - Barclays David Lebowitz ...
Blueprint Medicines(BPMC) - 2021 Q2 - Quarterly Report
2021-07-28 16:00
Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regi ...
Blueprint Medicines(BPMC) - 2021 Q1 - Earnings Call Transcript
2021-04-29 18:42
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2021 Earnings Conference Call April 29, 2021 8:30 AM ET Company Participants Kristin Hodous - Senior Manager, Investor Relations Jeff Albers - Chief Executive Officer Christy Rossi - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Marc Frahm - Cowen & Company Dane Leone - Raymond James Michael Schmidt - Guggenheim David Lebowitz - Morgan Stanle ...
Blueprint Medicines(BPMC) - 2021 Q1 - Quarterly Report
2021-04-28 16:00
Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Reg ...
Blueprint Medicines(BPMC) - 2020 Q4 - Earnings Call Transcript
2021-02-17 17:23
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2020 Results Conference Call February 17, 2021 8:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chief Commercial Officer Fouad Namouni - President, Research and Development Mike Landsittel - CFO Conference Call Participants Marc Frahm - Cowen and Company Dane Leone - Raymond James Charles Zhu - Guggenheim David Lebowitz - Morgan Stanley Peter Lawson - Barclays Arlinda Lee - Canaccord Eun Yang - Jefferies Mi ...
Blueprint Medicines(BPMC) - 2020 Q4 - Annual Report
2021-02-16 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact name of registrant as specified in its charter) Delaware 26-3632015 (St ...
Blueprint Medicines(BPMC) - 2020 Q3 - Quarterly Report
2020-10-29 20:18
Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of ...
Blueprint Medicines(BPMC) - 2020 Q3 - Earnings Call Transcript
2020-10-29 18:52
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2020 Earnings Conference Call October 29, 2020 8:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - COO Mike Landsittel - CFO Conference Call Participants Marc Frahm - Cowen and Company Reni Benjamin - JMP Securities Andrew Berens - SVB Leerink Peter Lawson - Barclays David Lebowitz - Morgan Stanley Nicole Gabreski - Piper Sandler Dane Leone - Raymond James Arlinda Lee - Canaccord Genuity Inc Michael Schmidt - ...
Blueprint Medicines(BPMC) - 2020 Q2 - Quarterly Report
2020-07-31 00:56
Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regi ...